Compare FLWS & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLWS | CRBU |
|---|---|---|
| Founded | 1976 | 2011 |
| Country | United States | United States |
| Employees | N/A | 97 |
| Industry | Other Specialty Stores | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 218.5M | 192.4M |
| IPO Year | 1999 | 2021 |
| Metric | FLWS | CRBU |
|---|---|---|
| Price | $4.93 | $1.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $10.75 |
| AVG Volume (30 Days) | 1.3M | ★ 1.4M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.64 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,151,921,000.00 | N/A |
| Revenue This Year | N/A | $1.63 |
| Revenue Next Year | N/A | $10.93 |
| P/E Ratio | $16.27 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.89 | $0.77 |
| 52 Week High | $8.44 | $3.53 |
| Indicator | FLWS | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 71.92 | 47.04 |
| Support Level | $3.03 | $1.70 |
| Resistance Level | $4.98 | $2.04 |
| Average True Range (ATR) | 0.47 | 0.12 |
| MACD | 0.09 | -0.03 |
| Stochastic Oscillator | 90.14 | 20.54 |
1-800-Flowers.com Inc is a provider of gifts designed to help customers express, connect, and celebrate. The company's e-commerce business platform features all brands, including 1-800-Flowers.com, 1-800-Baskets.com, Cheryl's Cookies, Harry and David, PersonalizationMall.com, Shari's Berries, FruitBouquets.com, Moose Munch, The Popcorn Factory, Wolferman's Bakery, Stock Yards, and Simply Chocolate. The company's business segments are; Consumer Floral and Gifts, BloomNet, and Gourmet Foods & Gift Baskets. The maximum revenue for the company is generated from its Gourmet Foods & Gift Baskets segment.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.